BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33340712)

  • 1. Association Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions?
    Arega MA; Yang DD; Royce TJ; Mahal BA; Dee EC; Butler SS; Sha S; Mouw KW; Nguyen PL; Muralidhar V
    Pract Radiat Oncol; 2021; 11(4):e426-e433. PubMed ID: 33340712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice?
    Muralidhar V; Rose BS; Chen YW; Nezolosky MD; Nguyen PL
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):313-317. PubMed ID: 27496390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy.
    Yang DD; Muralidhar V; Mahal BA; Beard CJ; Mouw KW; Martin NE; Orio PF; King MT; Nguyen PL
    Am J Clin Oncol; 2018 Oct; 41(10):953-959. PubMed ID: 29045266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
    Vetterlein MW; Löppenberg B; Karabon P; Dalela D; Jindal T; Sood A; Chun FK; Trinh QD; Menon M; Abdollah F
    Cancer; 2017 Sep; 123(17):3241-3252. PubMed ID: 28472547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Travel distance and stereotactic body radiotherapy for localized prostate cancer.
    Mahal BA; Chen YW; Sethi RV; Padilla OA; Yang DD; Chavez J; Muralidhar V; Hu JC; Feng FY; Hoffman KE; Martin NE; Spratt DE; Yu JB; Orio PF; Nguyen PL
    Cancer; 2018 Mar; 124(6):1141-1149. PubMed ID: 29231964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Yousefi K; Davicioni E; Ghadessi M; Johnson MH; Sundi D; Tosoian JJ; Han M; Humphreys EB; Partin AW; Walsh PC; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Mar; 69(3):496-504. PubMed ID: 25922274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy.
    García-Barreras S; Rozet F; Nunes-Silva I; Srougi V; Sanchez-Salas R; Barret E; Galiano M; Cathelineau X
    Clin Transl Oncol; 2018 Aug; 20(8):1004-1010. PubMed ID: 29243074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009.
    Mahal BA; Hoffman KE; Efstathiou JA; Nguyen PL
    Clin Genitourin Cancer; 2015 Jun; 13(3):e167-72. PubMed ID: 25554010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncologic outcomes at 10 years following robotic radical prostatectomy.
    Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
    Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy.
    Hawken SR; Spratt DE; Qi J; Linsell SM; Cher ML; Ghani KR; Miller DC; Montie JE; Morgan TM;
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1030-1034. PubMed ID: 30682490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer.
    Vicini FA; Ziaja EL; Kestin LL; Brabbins DS; Stromberg JS; Gonzalez JA; Martinez AA
    Urology; 1999 Jul; 54(1):111-7. PubMed ID: 10414736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.